Samuel T. Lockner | Iain A. McIntyre

Our client, Teva, faced charges of infringement of two patents covering Elan’s SODAS® technology used in connection with Focalin XR® (dexmethylphenidate) and other pharmaceutical drug products stemming from an abbreviated new drug application it filed with the FDA. Through our representation, Teva secured a favorable settlement agreement.